Modus Therapeutics Holding AB
We develop sevuparin to help patients with severe conditions and high unmet medical need.
Sweden
4 employees
Post-IPO Debt
Total: $190.50M
Biotechnology, Health and Wellness +1
General Information
Sweden
BounceWatch is an independent company data service, not affiliated with Modus Therapeutics Holding AB. To contact Modus Therapeutics Holding AB, visit modustx.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
Sweden Market
Biotechnology
About Modus Therapeutics Holding AB
Funding Rounds & Investors (4)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Debt | kr7.00M | 1 |
Karolinska
|
29 Mar 2023 |
| Post IPO Debt | kr11.50M | 1 |
Karolinska
|
12 May 2022 |
| Series A | kr140.00M | 1 |
|
13 Jul 2018 |
| Venture Round | kr32.00M | 4 |
|
20 Feb 2017 |
Modus Therapeutics Holding AB Alternatives & Competitors
View All Alternatives
Developing innovative therapeutics for diseases at confluence of fibrosis and inflammation with high...
Antibody Magic
Commercializing a key component of the immune system, #Gelsolin, for infectious, inflammatory and de...
FAQ About Modus Therapeutics Holding AB
Source: BounceWatch company record for Modus Therapeutics Holding AB, https://bouncewatch.com/company/modus-therapeutics, updated 24 October 2024. When citing, please name BounceWatch and link this page.
